LGALS3 and pulmonary fibrosis: A large body of evidence points to Gal-3 being an important mediator of fibrosis across multiple organs and pre-clinical work with TD139 has demonstrated the antifibrotic potential of targeting Gal-3 in lung fibrosis [6, 15].